LFCR LIFECORE BIOMEDICAL, INC. \DE\
Pharmaceutical Preparations · Nasdaq · SEC CIK 1005286 · Fiscal year ends 05/25
Financial factors as of 2025-05-25 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.5%
TTM net income YoY-422.3%
TTM EPS YoY-484.8%
Revenue 3-yr CAGR5.0%
Net income 3-yr CAGR—
Margins
Gross margin31.3%
Operating margin-13.4%
Net margin-30.0%
FCF margin-10.6%
EBITDA margin-7.2%
Returns
ROE-612.1%
ROA-15.7%
ROIC (approx.)-10.7%
Asset turnover0.52x
Leverage & solvency
Liabilities / assets80.2%
Debt / equity100.20x
Current ratio2.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.00x
Accruals ratio-15.6%
Payout ratio—
Capex / revenue10.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-05-25 | FY20242024-05-26 | FY20232023-05-28 | FY20222022-05-29 | FY20212021-05-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $128.87M | $128.26M | $103.27M | $111.27M | $100.87M |
| Cost of revenue | $88.57M | $86.41M | $75.28M | $72.20M | $61.94M |
| Gross profit | $40.30M | $41.85M | $27.98M | $39.07M | $38.94M |
| R&D expense | $8.26M | $8.57M | $8.74M | $7.84M | $6.68M |
| SG&A expense | $44.05M | $40.46M | $38.97M | $34.66M | $27.72M |
| Operating income | -$17.25M | -$8.84M | -$21.80M | -$11.79M | -$8.82M |
| Interest expense | $22.17M | $18.15M | $17.65M | $15.55M | $8.93M |
| Pretax income | -$38.67M | $9.51M | -$63.93M | -$20.69M | -$29.79M |
| Income tax | $43,000 | $183,000 | $308,000 | -$5.21M | -$6.35M |
| Net income | -$38.72M | $12.01M | -$99.56M | -$116.72M | -$32.29M |
| EBITDA | -$9.22M | -$890,000 | -$8.62M | $6.27M | $11.04M |
| EPS (basic) | -1.27 | 0.39 | -3.32 | -3.97 | -1.10 |
| EPS (diluted) | -1.27 | 0.33 | -3.32 | -3.97 | -1.10 |
| Weighted avg. shares (diluted) | 34.82M | 36.66M | 29.96M | 29.47M | 29.29M |
| Balance sheet | |||||
| Cash & equivalents | $8.27M | $8.46M | $19.09M | $1.64M | $1.29M |
| Receivables | — | $31.15M | $29.02M | $38.31M | $31.59M |
| Inventory | $32.29M | $39.98M | $40.84M | $36.00M | $33.93M |
| Current assets | $85.68M | $81.03M | $93.88M | $116.67M | $145.30M |
| PP&E, net | $129.01M | $149.16M | $134.39M | $118.67M | $107.13M |
| Goodwill | $13.88M | $13.88M | $13.88M | $13.88M | $13.88M |
| Intangibles | $4.20M | $4.20M | $4.20M | $1.07M | $8.04M |
| Total assets | $239.34M | $253.96M | $253.54M | $274.70M | $501.88M |
| Current liabilities | $30.18M | $38.87M | $39.29M | $176.58M | $101.85M |
| Short-term debt | $3.44M | $943,000 | $580,000 | $98.18M | $0 |
| Long-term debt | $130.44M | $124.67M | $84.26M | $0 | $164.90M |
| Total debt | $133.87M | $125.61M | $84.84M | $98.18M | $164.90M |
| Total liabilities | $191.91M | $200.06M | $218.46M | $186.88M | $299.94M |
| Shareholders' equity | $1.34M | $11.31M | -$4.23M | $87.82M | $201.95M |
| Net debt | $125.61M | $117.15M | $65.75M | $96.53M | $163.61M |
| Shares outstanding | 37.03M | 30.56M | 30.32M | 29.51M | 29.33M |
| Cash flow statement | |||||
| Operating cash flow | -$206,000 | $257,000 | -$17.44M | -$22.59M | $16.47M |
| Capital expenditure | $13.41M | $18.39M | — | $26.23M | $19.26M |
| Free cash flow | -$13.62M | -$18.14M | — | -$48.82M | -$2.79M |
| Investing cash flow | -$6.42M | -$18.39M | -$4.81M | $79.96M | -$12.31M |
| Financing cash flow | $6.42M | $7.51M | $39.70M | -$57.02M | -$3.42M |
| Depreciation & amortization | $8.03M | $7.95M | $13.18M | $18.06M | $19.87M |
| Stock-based compensation | $10.16M | $6.20M | $3.61M | $2.61M | $3.36M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.